for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Merck & Co., Inc.

MRK.N

Latest Trade

88.59USD

Change

-0.98(-1.09%)

Volume

556,908

Today's Range

88.47

 - 

89.59

52 Week Range

70.89

 - 

89.95

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
89.57
Open
89.18
Volume
556,908
3M AVG Volume
174.67
Today's High
89.59
Today's Low
88.47
52 Week High
89.95
52 Week Low
70.89
Shares Out (MIL)
2,545.98
Market Cap (MIL)
226,541.70
Forward P/E
17.23
Dividend (Yield %)
2.74

Next Event

Dividend For MRK.N - 0.6100 USD

Latest Developments

More

PDS Biotechnology Announces Principal Investigator And Independent Data Monitoring Committee For Its Phase 2 Clinical Collaboration With Merck

Merck & Co To Acquire Arqule For $20 Per Share In Cash

Lynparza (Olaparib) Approved In China As A First-Line Maintenance Therapy In BRCA-Mutated (BRCAm) Advanced Ovarian Cancer

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Merck & Co., Inc.

Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers, such as health maintenance organizations, pharmacy benefit managers and other institutions. Vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices.

Industry

Biotechnology & Drugs

Contact Info

2000 Galloping Hill Rd

+1.908.7404000

http://www.merck.com/

Executive Leadership

Kenneth C. Frazier

Chairman of the Board, President, Chief Executive Officer

Robert M. Davis

Executive Vice President, Global Services, Chief Financial Officer

Steven C. Mizell

Executive Vice President, Chief Human Resources Officer, Human Resources

Jim Scholefield

Executive Vice President, Chief Information and Digital Officer

Michael T. Nally

Executive Vice President, Chief Marketing Officer

Key Stats

1.82 mean rating - 17 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

39.8K

2017

40.1K

2018

42.3K

2019(E)

46.9K
EPS (USD)

2016

3.780

2017

3.980

2018

4.340

2019(E)

5.164
Price To Earnings (TTM)
23.92
Price To Sales (TTM)
4.93
Price To Book (MRQ)
8.46
Price To Cash Flow (TTM)
16.96
Total Debt To Equity (MRQ)
97.21
LT Debt To Equity (MRQ)
84.50
Return on Investment (TTM)
14.82
Return on Equity (TTM)
11.33

Latest News

Latest News

US STOCKS-Wall St falls as health, tech shares drag, tariff deadline looms

* Indexes down: Dow 0.3%, S&P 500 0.22%, Nasdaq 0.26% (Updates to late afternoon)

Merck pushes deeper into targeted cancer therapy with $2.7 billion ArQule deal

Merck & Co Inc <MRK.N> said on Monday it would buy ArQule Inc <ARQL.O> for $2.7 billion, as it looks to tap into the drug developer's experimental blood cancer therapy that targets genetic mutations.

Merck to buy cancer drug developer ArQule for $2.7 bln in cash

Merck & CO said on Monday it would buy cancer drug developer ArQule Inc for $2.7 billion in cash to beef up its portfolio of blood cancer treatments.

AstraZeneca-Merck Lynparza wins approval in China for ovarian cancer treatment

AstraZeneca Plc <AZN.L> and Merck & Co Inc <MRK.N> said on Thursday that their drug, Lynparza, won approval in China as a first line treatment for a form of ovarian cancer.

Merck and Bayer's heart drug meets main goal of late-stage study

Merck & Co Inc <MRK.N said on Monday an experimental treatment being developed with Bayer AG for patients with worsening chronic heart failure met the main goal of a late-stage study.

Merck and Bayer's heart drug meets main goal of late-stage study

Merck & Co Inc <MRK.N said on Monday an experimental treatment being developed with Bayer AG for patients with worsening chronic heart failure met the main goal of a late-stage study. The drug, vericiguat, reduced the risk of heart failure and hospitalization in patients...

Merck wins European approval for first-ever Ebola vaccine

U.S. drugmaker Merck & Co Inc on Monday received approval from the European Commission to market (http://bit.ly/2NZ0QMB) its Ebola vaccine, less than a month after a European medicines panel backed the first-ever vaccine against the deadly virus.

Merck wins European approval for first-ever Ebola vaccine

Merck & Co Inc on Monday received approval from the European Commission to market (http://bit.ly/2NZ0QMB) its Ebola vaccine, less than a month after a European medicines panel backed the first-ever vaccine against the deadly virus.

Johnson & Johnson files for European approval of Ebola vaccine

Johnson & Johnson <JNJ.N> said on Thursday it had filed for an approval from European regulators for its two-dose experimental vaccine to protect against Ebola, less than a month after the agency recommended approval of Merck & Co Inc's <MRK.N> vaccine.

Merck loses bid to revive $2.54 billion patent verdict against Gilead

A U.S. appeals court on Wednesday dealt a major blow to Merck & Co Inc <MRK.N> as it upheld a ruling that threw out a $2.54 billion jury verdict the drugmaker had won against Gilead Sciences Inc <GILD.O>.

Merck loses bid to revive $2.54 billion patent verdict against Gilead

A U.S. appeals court on Wednesday dealt a major blow to Merck & Co Inc as it upheld a ruling that threw out a $2.54 billion jury verdict the drugmaker had won against Gilead Sciences Inc.

US STOCKS SNAPSHOT-Merck, Pfizer spur S&P 500 to record high; Alphabet weighs on Nasdaq

The S&P 500 hit a fresh record high on Tuesday, lifted by upbeat earnings from drugmakers Merck and Pfizer, while disappointing quarterly profit from Google-parent Alphabet kept the Nasdaq firmly in the negative territory.

Merck sees ongoing Keytruda strength as its sales top $3 billion in quarter

Merck & Co Inc <MRK.N> on Tuesday said it expected immunotherapy Keytruda to continue its market dominance as an initial treatment for advanced lung cancer as sales of the drug topped $3 billion in a quarter for the first time, beating lofty Wall Street estimates.

US STOCKS SNAPSHOT-Wall Street dips at open after mixed earnings reports

Wall Street opened slightly lower on Tuesday as investors assessed a mixed batch of earnings reports, including from Google-parent Alphabet and big drugmakers Merck and Pfizer.

Merck to ramp up Gardasil vaccine production, flags 'tempered' sales growth in 2020

Merck & Co Inc <MRK.N> said on Tuesday it intends to ramp up production of its top-selling vaccine Gardasil in 2023 and warned of a slowdown in revenue growth next year as demand for the therapy outpaces supply.

CORRECTED-BRIEF-WHO Welcomes EMA Recommendation Of Conditional Marketing Authorization For Merck's V920 Ebola Zaire Vaccine

* WORLD HEALTH ORGANIZATION SAYS "WELCOMES" THE EMA ANNOUNCEMENT RECOMMENDING A CONDITIONAL MARKETING AUTHORIZATION FOR MERCK'S V920 EBOLA ZAIRE VACCINE

WHO hails 'triumph' as Merck's Ebola vaccine gets European green light

The world's first Ebola vaccine was recommended for approval by European drugs regulators on Friday in a move hailed by the World Health Organization (WHO) as a "triumph for public health" that would save many lives.

Merck gets EU panel nod for first ever Ebola vaccine

A panel of the European drugs regulator on Friday recommended approving Merck & Co's vaccine for the deadly Ebola virus.

US STOCKS-Apple and Merck drive Wall Street higher as trade worries abate

* Apple up on JPM's iPhone volume forecast raise, Cook's comments

AstraZeneca, Merck ovarian cancer treatment improves progression-free survival

AstraZeneca Plc <AZN.L> and Merck & Co Inc <MRK.N> said on Monday their treatment for newly diagnosed advanced ovarian

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up